Los Angeles Capital Management LLC Buys 47,563 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Los Angeles Capital Management LLC increased its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 110.7% during the 4th quarter, Holdings Channel reports. The fund owned 90,542 shares of the company’s stock after acquiring an additional 47,563 shares during the period. Los Angeles Capital Management LLC’s holdings in Inspire Medical Systems were worth $16,785,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. First Horizon Advisors Inc. boosted its stake in Inspire Medical Systems by 885.7% during the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 124 shares in the last quarter. True Wealth Design LLC acquired a new position in Inspire Medical Systems during the third quarter worth $30,000. Farther Finance Advisors LLC raised its holdings in Inspire Medical Systems by 1,158.3% during the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after buying an additional 139 shares during the last quarter. Signaturefd LLC raised its holdings in Inspire Medical Systems by 45.9% during the third quarter. Signaturefd LLC now owns 270 shares of the company’s stock worth $57,000 after buying an additional 85 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Inspire Medical Systems by 37.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock worth $68,000 after buying an additional 100 shares during the last quarter. 94.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

INSP has been the subject of several analyst reports. Bank of America upgraded shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and increased their target price for the company from $220.00 to $255.00 in a report on Wednesday, November 20th. Stifel Nicolaus lowered their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a report on Tuesday, January 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $260.00 target price on shares of Inspire Medical Systems in a report on Tuesday, February 11th. Truist Financial lowered their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, February 11th. Finally, Morgan Stanley lowered their target price on shares of Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Inspire Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $228.82.

Insiders Place Their Bets

In related news, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares of the company’s stock, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 26,225 shares of company stock valued at $4,806,530. 4.10% of the stock is currently owned by corporate insiders.

Inspire Medical Systems Stock Performance

INSP stock opened at $184.76 on Wednesday. The company has a market capitalization of $5.48 billion, a PE ratio of 106.80, a price-to-earnings-growth ratio of 2.86 and a beta of 1.32. Inspire Medical Systems, Inc. has a one year low of $123.00 and a one year high of $257.40. The company’s 50 day moving average price is $187.75 and its two-hundred day moving average price is $193.21.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, research analysts predict that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.